Cellectis Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cellectis stock.
View analyst ratings for Cellectis or view top-rated stocks.

Wall Street analysts have given Cellectis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cellectis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cellectis saw a increase in short interest in May. As of May 14th, there was short interest totaling 1,480,000 shares, an increase of 28.7% from the April 29th total of 1,150,000 shares. Based on an average trading volume of 326,300 shares, the short-interest ratio is currently 4.5 days.
View Cellectis' Short Interest.

Cellectis is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Cellectis.

Cellectis S.A. (NASDAQ:CLLS) issued its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.28) EPS for the quarter, topping the Zacks' consensus estimate of ($0.82) by $0.54. The biotechnology company had revenue of $27.97 million for the quarter, compared to the consensus estimate of $8.14 million. Cellectis had a negative net margin of 200.21% and a negative trailing twelve-month return on equity of 36.24%.
View Cellectis' earnings history.

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLLS shares have increased by 32.3% and is now trading at $15.12.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued 12 month price objectives for Cellectis' stock. Their forecasts range from $32.00 to $39.00. On average, they anticipate Cellectis' share price to reach $34.67 in the next twelve months. This suggests a possible upside of 129.3% from the stock's current price.
View analysts' price targets for Cellectis or view top-rated stocks among Wall Street analysts.

4 employees have rated Cellectis CEO André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among Cellectis' employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Cellectis include Revolution Medicines (RVMD), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Instil Bio (TIL), Rubius Therapeutics (RUBY), bluebird bio (BLUE), Kymera Therapeutics (KYMR), Alector (ALEC), Sangamo Therapeutics (SGMO), Immunocore (IMCR), Replimune Group (REPL), REGENXBIO (RGNX), C4 Therapeutics (CCCC), Cortexyme (CRTX) and ImmunityBio (IBRX).
View all of CLLS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.26%), Sumitomo Mitsui Trust Holdings Inc. (1.96%), Nikko Asset Management Americas Inc. (1.96%), Capital Impact Advisors LLC (0.76%), Morgan Stanley (0.57%) and BlackRock Inc. (0.43%).

CLLS stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, 683 Capital Management LLC, Morgan Stanley, D. E. Shaw & Co. Inc., HRT Financial LP, WS Management Lllp, and Kennedy Capital Management Inc..

CLLS stock was bought by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC, Prosight Management LP, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Exchange Traded Concepts LLC, Mirae Asset Global Investments Co. Ltd., Henry James International Management Inc., and BlackRock Inc..

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLLS stock can currently be purchased for approximately $15.12.

Cellectis has a market capitalization of $687.37 million and generates $82.46 million in revenue each year. The biotechnology company earns $-81,070,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

Cellectis employs 272 workers across the globe.

The official website for Cellectis is www.cellectis.com.

Cellectis is headquartered at 8 RUE DE LA CROIX JARRY, PARIS I0, 75013.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]